Diabetic Gastroparesis Treatment Market Share, Growth, Opportunitites, Analysis, Trends, Market Size, and Forecasts 2019 - 2027
![]() |
Diabetes can cause a variety of medical conditions in humans, including gastroparesis, a stomach condition. Diabetic gastroparesis is characterised by a loss of the digestive tract's ability to digest food in a timely manner. This causes food to stay in the stomach for longer than usual, resulting in vomiting and nausea. Diabetes's rising prevalence fuels the growth of the global diabetic gastroparesis treatment market. Furthermore, the presence of a streamlined health care industry focused on rapid treatment and diagnosis has fueled market growth. Diabetic gastroparesis can have an impact on a patient's quality of life. As a result, medical practitioners have taken such disorders very seriously.
The absence of clinical evidence on the efficacy of prescription drugs is expected to stifle growth in the global diabetic gastroparesis treatment market. Prescription drugs for the treatment of diabetic gastroparesis have very little documented clinical evidence. Diabetic gastroparesis is treated with metoclopramide, domperidone, and erythromycin. However, approvals of these drugs vary across countries, resulting in a lack of consistent patient improvement data as a result of their administration. In emerging economies, the disease is largely untreated or is frequently treated with non-prescription OTC drugs, which contributes to a lack of clinical evidence regarding improvements in quality of life for patients after consuming these drugs for the treatment of diabetic gastroparesis.
Measures to support product approval and labelling claims for diabetic gastroparesis treatments are expected to provide lucrative growth opportunities for global diabetic gastroparesis treatment market participants. In February 2019, for example, a team of researchers affiliated with Boston Therapeutics, Inc. reported that The Diabetic Gastroparesis Symptom Severity Diary can be used to derive endpoints to evaluate treatment benefit in future diabetic gastroparesis interventional trials.
The major players operating in the global diabetic gastroparesis treatment market include, Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
Comments
Post a Comment